Rein Therapeutics (RNTX) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rein Therapeutics (RNTX) has outperformed Tenax Therapeutics (TENX) over the past year, losing 44.7% versus a loss of 76.2%. Over five years, RNTX leads with a -96.2% price change compared with -99.9% for TENX. Rein Therapeutics is the larger company by market cap ($68.1 million vs $68.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNTX | TENX |
|---|---|---|
| Share price | $0.7899 | $1.82 |
| Market cap | $68.14M | $68.11M |
| 1-day change | +2.68% | -2.15% |
| YTD return | -33.68% | -84.74% |
| 1-year return | -44.65% | -76.25% |
| 5-year return | -96.19% | -99.93% |
| EPS (TTM) | $-1.68 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.18 | $19.40 |
| 52-week low | $0.694 | $1.31 |
| Distance from 52-week high | -63.77% | -90.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +659.59% | +590.11% |
| Average volume | 430.81K | 5.46M |
| Shares outstanding | 86.27M | 37.42M |
| Employees | 10 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNTX has outperformed TENX by 31.6 percentage points over the past year.
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
RNTX vs TENX FAQ
Which is bigger, Rein Therapeutics or Tenax Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $68.14M compared with $68.11M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, RNTX or TENX?
RNTX returned -44.65% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Rein Therapeutics and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.